Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 8175 Shares

Retrieved on: 2023-12-27 15:28:42

Tags for this article:

Financial markets

Alternative investment management companies

Hedge funds

Marketbeat

Sioux Falls, South Dakota

Short

Enliven Therapeutics Inc.

Click the tags to see associated articles and topics

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 8175 Shares. View article details on HISWAI: https://www.marketbeat.com/instant-alerts/nasdaq-elvn-insider-buying-and-selling-2023-12-26/

Excerpt

BlackRock Inc. now owns 1,546,475 shares of the company's stock valued ... Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company ...

Article found on: www.marketbeat.com

View Original Article